hit counter

Adult ADHD Trials Often Skip Full Diagnostic Assessment

MHD featured image for adult ADHD randomized trials and diagnostic assessment quality.

A 2025 scoping review of 292 adult ADHD randomized controlled trials found that 49.7% allocated diagnosis without a general psychopathology assessment, and only 35% reported that psychiatrists or psychologists assigned the ADHD diagnosis. Research Highlights 292 adult ADHD RCTs were reviewed: Studart et al. screened 706 PubMed records and included 292 randomized controlled studies.1 49.7% …

Read more

Prader-Willi Syndrome: New Treatments & Medications in Development & Clinical Trials (2023)

Prader-Willi Syndrome (PWS) is a rare genetic condition marked by a diverse range of physical, mental, and behavioral challenges. Characterized by uncontrolled appetite and obesity, cognitive impairments, and social and behavioral issues, PWS presents unique challenges for patients and caregivers. Highlights: Prevalence and Genetics: PWS affects approximately 1 in 20,000 live births, caused by errors …

Read more

Dextromethorphan-Bupropion (Auvelity) for Depression: Clinical Trial Data for the New Rapid-Acting Antidepressant

Major depressive disorder (MDD) is a significant global health concern, affecting over 280 million people worldwide. While numerous pharmacological options exist, challenges remain in achieving timely, robust, and sustained antidepressant response. Dextromethorphan-bupropion is a novel oral antidepressant recently approved by the FDA for MDD in adults that may address some of these unmet needs. Key …

Read more

9 New Anxiety Medications (2018): Drugs In Clinical Trials

Collected data from the Anxiety and Depression Association of America (ADAA) suggests that upwards of 40 million adults are affected by anxiety, or approximately 18% of the United States population.  Among the 40 million adults who are affected by anxiety, it is estimated that approximately: 19 million suffer from specific phobias; 15 million suffer from …

Read more

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder.  In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient.  The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

Read more

6 New Autism Medications (2015): Drugs In Clinical Trials

Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder that significantly affects behavior, cognitive function, and social skills.  Those with the disorder often engage in repetitive behaviors, suffer from low intelligence, and have severe difficulty verbalizing their thoughts.  In fact, a subset individuals with autism are incapable of any verbal communication and resort to gesturing …

Read more

3 New Narcolepsy Medications (2015) In Clinical Trials

Narcolepsy is a neurological disorder associated with the brain’s inability to regulate sleep-wake cycles (and the circadian rhythm).  As a result, individuals diagnosed with narcolepsy often experience excessive daytime sleepiness and may fall asleep unexpectedly.  Some have suggested that the excessive daytime sleepiness stemming from narcolepsy is akin to how a normal person feels if …

Read more